New target for treatment resistance after EGFR inhibitors found in lung cancer study Isra Zaman14 Feb 2023 9:15 AM ISTApproximately 10-15% of patients with NSCLC have EGFR mutations. While treatment with EGFR TKIs is effective at killing most cancer cells, a small...
Wellmarker Bio enters clinical trial collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA Ruchika Sharma9 Feb 2023 2:15 PM ISTWM-A1-3389 is a novel therapeutic antibody targeting a new immune checkpoint protein discovered by Wellmarker Bio and has demonstrated efficacy across...
Setback to AstraZeneca: Imfinzi fails as monotherapy for non-small lung cancer Ruchika Sharma20 Dec 2022 1:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
Novartis gets CDSCO panel nod to study anticancer drug JDQ443 Dr. Divya Colin17 Dec 2022 6:00 PM ISTNew Delhi: Pharmaceutical major Novartis, has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Submit Phase IV CT protocol: CDSCO Panel tells Roche over Anti-Cancer drug Pralsetinib Dr. Divya Colin16 Dec 2022 6:00 PM ISTNew Delhi: Reiterating the earlier recommendation regarding the condition of conduct a Phase IV clinical trial of anti-neoplastic drug Pralsetinib,...
USFDA declines to approve Spectrum Pharma lung cancer drug Poziotinib Ruchika Sharma26 Nov 2022 4:04 PM ISTBoston: Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, has announced that the...
AstraZeneca gets USFDA nod for Imfinzi, Imjudo with chemotherapy to treat metastatic non-small cell lung cancer Ruchika Sharma11 Nov 2022 2:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
Repotrectinib could be effective for treating ROS1 positive NSCLC: TRIDENT-1 trial Isra Zaman31 Oct 2022 9:30 AM ISTRepotrectinib has been designed to help patients with NSCLC that have a genetic rearrangement in their tumour cells called ROS1positive that can...
Targeted lung cancer drug repotrectinib shows promise in TRIDENT-1 trial Dr. Kamal Kant Kohli29 Oct 2022 4:45 AM ISTResearchers have found in TRIDENT-1 trial that targeted drug repotrectinib could help treat patients with a certain type of non-small cell lung...
Phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer shows positive headline results: GSK Ruchika Sharma9 Oct 2022 2:00 PM ISTJemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands...
Thermo Fisher Scientific bags USFDA nod for NGS-based CDx Test for lung, thyroid cancers Ruchika Sharma28 Sept 2022 12:45 PM ISTThe Oncomine Dx Target test is a next-generation sequencing (NGS)-based test that can detect multiple alterations at once from a small sample size,...
USFDA nod to Eli Lilly RET Inhibitor Retevmo for adults with advanced or metastatic solid tumors with a RET Gene Fusion, regardless of type Ruchika Sharma23 Sept 2022 4:20 PM ISTIn addition to the tumor-agnostic approval, the USFDA has granted traditional approval for Retevmo in adult patients with locally advanced or...
